Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
NextCure, Inc.: Amended and restated bylaws to update adjournment procedures, stockholder meeting lists, director nomination rules, and universal proxy rules compliance (effective 2023-06-22).
- Change
- bylaw amendment
- Effective
- 2023-06-22
Exact text from the filing
On June 22, 2023, the board of directors (the “Board”) of NextCure, Inc. (the “Company”) approved and adopted the Second Amended and Restated Bylaws of the Company (the “A&R Bylaws”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
NextCure, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 at the 2023-06-22 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-22
Exact text from the filing
On June 22, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders: (i) elected the three Class I members of the Board, each to serve for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until such director’s earlier death, resignation, or removal from the Board; and (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
NextCure, Inc. shareholders approved Election of Class I Directors at the 2023-06-22 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-22
Exact text from the filing
On June 22, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders: (i) elected the three Class I members of the Board, each to serve for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until such director’s earlier death, resignation, or removal from the Board; and (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov